How much does a box of deuterated colexitinib cost in 2024?

Deuterated colexitinib is currently on the market in China. However, since it is not included in the medical insurance list, patients need to pay for the drug at their own expense. According to the latest data, the price of 6mg*7 tablets of deuterated colexitinib in the domestic market is approximately 1,500 RMB.

In comparison, the price of the overseas original drug 6mg30 tablets of deuterated colexitinib is about 5 yuan. The latest price of the generic deuterated colexitinib 6mg30 tablets in Bangladesh Ziska is only about a few hundred yuan. Therefore, patients can choose to purchase drugs that suit them according to their own needs and financial situation. When purchasing drugs, patients should choose carefully and make decisions based on the guidance of their doctor. In addition, patients can communicate with their doctors or pharmacists to learn more about their medications so they can make informed choices.

Deuterated colexitinib is the world's first approved TYK2 inhibitor. By specifically inhibiting the activity of TYK2, it blocks the downstream signal transduction and transcription activation (STAT) processes, thereby regulating the activation and proliferation of immune cells to achieve the purpose of treating diseases. As a highly selective TYK2 inhibitor, deuterated colexitinib inhibits TYK2 while also affecting other related The inhibitory effect of off-kinases (such as JAK1, JAK2, etc.) is weak, which helps to reduce the occurrence of adverse reactions.

Clinical trial data show that deuterated colexitinib shows good safety and tolerability in the treatment of moderate to severe plaque psoriasis. Common adverse reactions include upper respiratory tract infection, nasopharyngitis, etc., and most of them are mild to moderate.

Indications

Deuterated colexitinib is primarily indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Psoriasis is a common chronic, relapsing, and inflammatory skin disease. Its clinical manifestations are mainly erythema and scales, and it can occur all over the body. The launch of deuterated colexitinib provides a new treatment option for these patients.